Claims

1. Use of an extracellular matrix modulating agent in the manufacture of a medicament for the prevention and/or suppression of guttae formation, wherein the agent comprises 1-(4-fluoro-5-iso quinolinesulfonyl)-2-methyl-1,4- homopiperazine or a salt thereof, or a solvate thereof.

2. Use of an extracellular matrix modulating agent in the manufacture of a medicament for the prevention and/or suppression of the recurrence of guttae formation, wherein the agent comprises 1-(4-fluoro-5-iso quinolinesulfonyl)-2-methyl-1,4- homopiperazine or a salt thereof, or a solvate thereof.

3. The use according to claim 1 or claim 2, wherein the medicament is to be administered to a Fuchs endothelial corneal dystrophy (FECD) patient.

4. The use of claim 3, wherein the patient is an early stage FECD patient.

5. The use according to any one of the preceding claims, wherein the medicament is a liquid formulation.

6. The use according to any one of the preceding claims, wherein the medicament is an eye drop.